Recombinant human GH (rhGH) is administered by once daily subcutaneous injections in a fashion very similar to the way in which a diabetic patient self-administers insulin. Patients are often started on a low initial dose, with dose increases based on clinical response and serum IGF-1 levels adjusted to the mid-normal range for age and gender. GH therapy has been shown to improve lean body mass, bone density, exercise tolerance, personal productivity and quality of life. The most common side effects are fluid retention and muscle/joint aches. These side effects are largely dose related, and these symptoms can be minimized by starting with a low initial dose and/or dose reductions.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.